Matrix metalloproteinases (MMPs) are zincbased catalytic enzymes responsible for maintaining tissue allostasis. These enzymes are active at neutral pH and can catalyze the normal turnover of extra cellular matrix (ECM) macromolecules, including the interstitial and basement membrane collagens, as well as proteoglycans and accessory ECM proteins, such as fibronectin. Members of the MMP family include the "classical" MMPs, the membrane-bound MMPs (MT-MMPs), the ADAMs (a disintegrin and metalloproteinase; adamlysins) and the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motif) (Malemud 2006) . There are more than 20 members in the MMP and ADAMTS family, including the collagenases, gelatinases, stromelysins, some elastases and aggrecanases (Table 1 , Tayebjee et al. 2005c) .
Most of the MMPs are synthesized as inactive latent enzymes, with conversion to the active enzyme mediated by activator systems that include plasminogen activator or the pro-hormone convertase, furin. MMP activity per se is regulated by a group of endogenous proteins, called, tissue inhibitor of metalloproteinases (TIMPs) that bind to active and alternative sites of the activated MMP (Malemud 2006) .
Why are these enzymes important ? The ECM is a vital component of connective tissue, and collagen is a major constituent, with elastin and other more specialized proteins, such as fibrillin and fibronectin, and proteoglycans being some of the other structural elements involved. Importantly, the ECM, both vascular and cardiac, is essential for structural support, cell-cell interaction and growth factor signaling. The ECM can be affected by various stimuli that include physical stretch, arterial pressure, inflammation, ischemia, and local effects of growth factors and cytokines. Of note, ECM turnover can be beneficial (e.g., organ repair) and can also be detrimental (Tayebjee et al. 2003 (Tayebjee et al. , 2005c .
Left ventricular hypertrophy (LVH) is a well known manifestation of hypertensive target organ damage and is an independent predictor of cardiovascular events. The presence of LVH is associated with both increased collagen content in the myocardium and perivascular tissues, as well as qualitative changes in the type I to type III collagen ratio, favoring stronger, but less compliant type I fibrils. An increase in type I collagen and increased collagen turnover in hypertension has been postulated to play a key role in increasing myocardial stiffness (Tayebjee et al. 2003) .
The ECM is hypothesized to impede left ventricular diastolic filling, thus contributing to symptomatic diastolic dysfunction (DD) in diabetic and hypertensive patients. For example, Tayebjee et al. (2005b) investigated circulating TIMP-1 levels as a marker of diastolic dysfunction in patients with type 2 diabetes and hypertension, and found a negative correlation between TIMP-1 levels and early mitral annular velocity on tissue Doppler (e', a recognized index of diastolic relaxation). This correlation was strongest amongst their hypertensive population (Spearman r = −0.544, p = 0.001), suggesting that TIMP-1 was an important mediator of diastolic compliance, independent of the underlying disease or mechanism. TIMP-1 is also suspected to be involved in scar formation, inhibiting the breakdown of ECM and enhancing fibrosis. Unsurprisingly, raised levels of TIMP-1 in hypertension are associated with LVH and myocardial fibrosis (Tayebjee et al. 2005c) . Other studies exploring a relationship between MMPs, their inhibitors and LV function are summarized in Table 2 .
Furthermore, abnormal levels of MMPs and their inhibitors are associated with other conditions, such as peripheral arterial disease (PAD), stable coronary artery disease and gestational hypertension (Tayebjee et al. 2005a, d, e) . For example, in a study of patients with intermittent claudication and critical limb ischemia, all with angiographically proven PAD, circulating levels of MMP-9 and TIMP-1 were found to be high, especially in those with critical ischemia (Tayebjee et al. 2005e) .
In this issue of Tohoku J. Exp. Med., a study by Saglam et al. (2006) adds further weight to the hypothesis that plasma MMPs play a role in the development of LVH and diastolic dysfunction in hypertensive subjects. Their study group included 27 hypertensive patients with LVH and 23 without LVH; they found that plasma MMP-3 and Sundstrom et al. (2004) TIMP-1 1069 Plasma TIMP-1 was positively associated with LV mass, wall thickness, relative wall thickness, end-systolic diameter, and LA diameter, increased LVEDD or wall thickness, and negatively correlated with fractional shortening. Noji et al. (2004) MMP-2, 3, 9 TIMP-1, 2 78 MMP-2 and TIMP-2, but not MMP-3, 9 and TIMP-1 positively correlated with LV diameters in patients with hypertrophic cardiomyopathy and negatively with fractional shortening. Soejima et al. (2003) MMP-1 46 MMP-1 correlated negatively with LV ejection fraction in patients with acute myocardial infarction. Lindsay et al. (2002) TIMP-1 150 TIMP-1 significantly elevated in patients with diastolic dysfunction and correlated with markers of diastolic filling. Timms et al. (2002) TIMP-1 48 Significant correlation between TIMP-1 and LV mass index and LVPWd in untreated hypertensive patients.
Li-Saw-Hee et al.
MMP-9, TIMP-1 56 No significant correlation between MMP-9 and TIMP-1 levels and systolic and diastolic blood pressures, LV mass, LV mass index and Doppler indices of diastolic dysfunction.
MMP, matrix metalloproteinase; TIMP, tissue inhibitor of metalloproteinase; LV, left ventricle; LVEDD, left ventricular end-diastolic diameter.
MMP-9 levels were significantly higher in patients with LVH. There was a correlation between MMP-3 and MMP-9 levels and conventional and tissue Doppler indices of diastolic dysfunction, only amongst patients with LVH. However, this was a small cross-sectional study, with none of the patients on drugs that block the renin-angiotensin system (angiotensin converting enzyme [ACE] inhibitors or angiotensin receptor blockers [ARBs]). Cross-sectional studies also show associations, rather than causality. One previous study (Li-Saw-Hee et al. 2000) explored the potential effects of treating hypertensive patients with an ACE-inhibitor or an ARB, albeit for a short period of time (about 2 months) and found no significant alteration in the MMP-9 and TIMP-1 levels, despite a fall in blood pressure (average treated blood pressure 143/85 mmHg). A follow up of the patients with LVH in the study by Saglam et al. (2006) , after treatment with an ACE-inhibitor or an ARB to assess for LVH regression as well as a fall in the MMP levels, that can be linked to a change in indices of diastolic dysfunction, would be interesting. Certainly, other short term treatment studies (Zervoudaki et al. 2003) suggest that this may potentially be the case. Also, the present study by Saglam et al. (2006) was limited to assays of only 2 out of the over 20 members of MMPs, with no corresponding assay of their inhibitor, TIMP-1. TIMP-1, as discussed above, has been shown in 4 out of the 7 studies to be related to LV mass, mass index and parameters of diastolic dysfunction ( Table 2) .
The time has perhaps come for a large longitudinal study to investigate the relationship between hypertension and cardiovascular disease in subjects at risk of -as well as those withproven target organ damage and abnormalities of collagen metabolism. In particular, we need to investigate the long-term prognostic effects, whether positive or negative, of modern drug management of hypertension that almost certainly includes agents that block the renin-angiotensin system (ACE inhibitors, ARBs) and statins. Important links of ECM abnormalities to other pathophysiological pathways that are present in hypertension, such as inflammation (Boos and Lip 2005) , arterial stiffness (McEniery and Wilkinson 2005) , endothelial damage/dysfunction (Schram et al. 2005 ) and the prothrombotic state (Varughese and Lip 2005) also need investigation, to comprehensively determine the "big picture" of the pathogenesis of hypertensive target organ damage. Only then can we improve our holistic management of patients with hypertension (Williams et al. 2004 ).
